flow trial semaglutide renal outcomes 2024 Long-term kidney of in obesity and cardiovascular disease in the SELECT FLOW Trial a kidney outcomes

Its pivotal TRIUMPH-1 trial, detailed at the American Diabetes Association meeting on 6 June, recorded average weight loss near 28.3% at 80 weeks on the top dose, climbing toward 30.3% at 104 weeks in a higher-BMI extension

Find your people

Semaglutide users were less likely to add new glucose-lowering treatment (hazard ratio [HR] 0.57

Fatigue is another commonly reported symptom, particularly during the early weeks

These variations may have contributed to the observed heterogeneities in the data

Options range from hormone therapy to exercise routines, with strategies that protect bone health, heart health, and mental well-being